|
Patent landscape, scope, and claims: |
US Patent 11,744,816 Scope, Claims, and U.S. Patent Landscape for LDL-C Lowering with 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic Acid + Ezetimibe
Executive summary: U.S. Patent 11,744,816 claims a specific method for lowering LDL-C in a subject with familial hypercholesterolemia (FH) using a specific 180 mg dose of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (8-OH TDEA) plus 10 mg ezetimibe, with claim scope focused on combination administration, and dependent claims extending into fixed-dose combination (tablet), biomarker effects (hsCRP), VLDL reduction, cardiovascular risk reduction, once-daily dosing, and human subjects. The enforceable U.S. value is therefore tied to: (i) patient selection (FH), (ii) the exact dosing and drug identities, and (iii) the claimed method endpoints/indications. Where generics seek to enter, design-around will usually focus on avoiding one of the claim elements, especially FH targeting, the 180 mg / 10 mg regimen, fixed-dose/tablet form, or the asserted biomarker and risk claims’ required correlation to the method.
What does US Patent 11,744,816 claim for LDL-C lowering with 8-OH TDEA and ezetimibe?
Core claim (Claim 1) defines infringement around a defined drug pair, dose, and indication:
- Method of lowering LDL-C in a subject “in need thereof”
- Administering:
- 180 mg 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
- 10 mg ezetimibe
- Subject limitation: familial hypercholesterolemia
Scope read-through for Claim 1
- “Administering” is broad enough to cover any administration route that yields the claimed effect (the claim text you provided does not limit route).
- The claim is dose- and combination-specific. Even if the same two agents are given, 180 mg and 10 mg are the key anchors.
- The claim is method-of-use, not composition-of-matter. That typically means:
- A generic cannot infringe by selling the two drugs alone.
- Infringement is tied to use in the claimed method context (FH patients receiving the regimen).
- The “in need thereof” language can be interpreted broadly, but the FH limitation is explicit. Use in non-FH hypercholesterolemia is outside the literal claim.
Claim construction risk points (practical)
- Dose precision: If the accused regimen uses a different dose than 180 mg 8-OH TDEA or different ezetimibe dose than 10 mg, literal infringement is less likely. Doctrine-of-equivalents arguments depend on the statutory framework and claim-by-claim prosecution history, but the claim as written is dose-anchored.
- Patient phenotype: If the accused protocol treats “high LDL-C” patients without FH diagnosis, it avoids a key limitation.
- Endpoint linkage: Claims 3–5 reference hsCRP, VLDL, and cardiovascular disease risk. These can become proof-intensive in litigation.
How broad are the dependent claims (2-8) in US 11,744,816?
Fixed-dose combination and tablet limitations (Claim 2 and Claim 7)
- Claim 2: the 8-OH TDEA and ezetimibe are administered as a fixed-dose combination.
- Claim 7: the fixed-dose combination is formulated to be a tablet.
Practical effect
- If a competitor administers the drugs as separate dosage forms (not fixed-dose) or uses a different delivery system (capsules, sachets, injections), Claim 2 and Claim 7 can be avoided while still potentially implicating Claim 1 (depending on whether Claim 1 is asserted alone in a lawsuit).
- For enforcement leverage, the fixed-dose/tablet claims give a second “claim layer” that can catch product-level infringers (sponsors selling a combined tablet for this specific regimen and indication).
Biomarker and surrogate effect claims (Claim 3 and Claim 4)
- Claim 3: administering decreases C-reactive protein (hsCRP).
- Claim 4: administering reduces very low density lipoprotein (VLDL).
Practical effect
- These are outcome-linked limitations. In practice, litigation focuses on trial design and data comparability:
- What timepoints and assay methods are used for hsCRP?
- How is VLDL measured?
- If a competitor’s protocol achieves LDL-C lowering in FH patients but does not target hsCRP reduction (or shows no statistically meaningful reduction), this can matter for the validity and infringement analysis of the dependent claims.
Cardiovascular risk claim (Claim 5)
- Claim 5: administration reduces the risk of a cardiovascular disease.
Practical effect
- “Reduces the risk” often drives disputes around:
- Whether risk was measured directly (events) or inferred through surrogate endpoints.
- Whether the claimed study population matches the FH subgroup.
- This claim can increase the evidentiary burden in enforcement, but it also gives stronger indication marketing support if the applicant has clinical endpoints.
Dosing frequency limitation (Claim 6)
- Once daily administration.
Practical effect
- If a competitor uses twice daily or intermittent dosing, they may avoid Claim 6 while still potentially infringing Claim 1.
Human subject (Claim 8)
This is largely a formality limitation for a clinical regimen; it rarely provides an actionable design-around.
What is the infringement theory for combinations versus separate administration under US 11,744,816?
Best reading from the claim set you provided
- Claim 1 does not require fixed-dose; it requires administration of both agents at the specified doses to an FH patient for LDL-C lowering.
- Claim 2 and Claim 7 add fixed-dose and tablet requirements.
Implications
- A competitor using separate products (two NDCs, separate administrations) can still potentially infringe Claim 1 if it matches the dosing and FH patient selection.
- A competitor using a fixed-dose combination tablet that matches doses and indication is exposed to both Claim 1 and dependent claims.
When does US 11,744,816 lose exclusivity in the United States?
No exclusivity timeline can be produced from the claim text alone. Loss of exclusivity depends on:
- patent issue date and statutory expiration (term)
- any PTA (patent term adjustment)
- any PTE (if applicable)
- filing history (non-provisional/priority)
- whether the patent is listed in the FDA Orange Book for the relevant NDA/ANDA and tied to an exclusivity-listed product
As requested, no incomplete exclusivity timeline is provided.
What Orange Book status applies to US Patent 11,744,816 and how does it affect generic risk?
The Orange Book status cannot be derived from the claim set alone. Orange Book relevance requires the patent’s listed:
- NDA/ANDA numbers
- submission type (e.g., method-of-use vs composition)
- claim type code / use code linking
No Orange Book listing assessment is provided without the underlying Orange Book record.
What other U.S. patents likely cover 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (8-OH TDEA) + ezetimibe regimens?
Based on the claim structure, the likely neighboring U.S. patent “clusters” in this area generally include:
- composition-of-matter for 8-OH TDEA (if patented as a small molecule)
- formulation patents for fixed-dose tablets containing 8-OH TDEA + ezetimibe
- method-of-use patents for LDL-C lowering in defined populations (FH and/or high-risk cardiovascular cohorts)
- biomarker-linked claims (hsCRP) and lipoprotein metrics (VLDL)
- dosing regimen patents (once daily, titration schedules)
- combination rationales (synergy language appears in many applications, but this claim set is outcome- and regimen-focused)
However, without access to the actual US patent family members and prosecution history tied to 11,744,816, listing specific patent numbers, assignees, and expiration dates would be speculative.
No specific additional patent numbers are provided.
How strong is the patent estate for LDL-C lowering in familial hypercholesterolemia using 8-OH TDEA + ezetimibe?
Claim-strength assessment strictly from the claim text provided
- Strength factors
- Precise dosing (180 mg + 10 mg) reduces the space for “close-but-not-the-same” regimen workarounds.
- FH limitation is a concrete patient subgroup restriction.
- Dependent claims provide layered fallback positions: fixed-dose/tablet, hsCRP, VLDL, cardiovascular risk, once daily.
- Weakness factors
- Method-of-use claims are fact-intensive and can be vulnerable if the accused regimen differs in patient inclusion criteria, dose, dosing frequency, or achieves different biomarker outcomes.
- If a competitor uses the two drugs at different doses or in a broader non-FH population, literal infringement of Claim 1 can be avoided.
Net: The estate strength depends on whether the commercial product(s) and real-world prescribing follow the claimed regimen in FH patients and whether the clinical evidence supports hsCRP/VLDL/cardio-risk statements. The claims are tailored enough to support meaningful enforcement if the marketed use matches.
Which generic entry risks exist for 8-OH TDEA + ezetimibe combinations?
Generic and “biosimilar” risk concepts do not map cleanly here because:
- ezetimibe is generic-available broadly, but the exposure risk hinges on the novel component (8-OH TDEA) and the claimed method.
- The key litigation risk for an ANDA filer is typically whether it can carve out the claimed use or whether it is positioned to trigger Paragraph IV defenses.
Without Orange Book listing and Orange Book claim codes tied to 11,744,816, it is not possible to determine:
- whether a generic would be required to certify against this patent
- which certification type (Paragraph IV vs I/II/III) would apply
- whether a product launch would “at-risk” infringe in the U.S.
No certification or launch scenario is provided.
What patent litigation and settlements affect US 11,744,816?
No litigation docket, asserted claims, or settlement agreements can be identified from the claim text you provided alone. Litigation impact requires:
- parties (NDA holders, ANDA applicants)
- district court/case numbers
- asserted claim mapping
- any stipulations, consent judgments, or licensed launch carve-outs
No litigation coverage is provided.
How does US 11,744,816 compare with other combination LDL-C patents (ezetimibe-based add-ons)?
From a claim-design standpoint, the differentiators in 11,744,816 are:
- the combination includes ezetimibe plus a specific LDL-C-active adjunct defined chemically (8-OH TDEA)
- the regimen is limited to familial hypercholesterolemia
- the claim incorporates specific downstream measurable outcomes (hsCRP, VLDL, cardiovascular risk) in dependent claims
Competitors with different ezetimibe combinations typically differentiate on:
- different active adjuncts
- different dosing
- different patient selection
- different endpoints or trial context
No comparative patent-number mapping is provided without a defined set of comparator patents and families.
What formulations are protected by US 11,744,816?
From the claims:
- A protected formulation exists only to the extent of Claim 7, which ties the fixed-dose combination to a tablet.
- Claim 2 covers fixed-dose combinations generally, but does not require tablet unless Claim 7 is asserted.
Protected product pattern (minimum)
- Fixed-dose tablet containing 8-OH TDEA and ezetimibe
- Administered once daily
- At doses corresponding to 180 mg 8-OH TDEA and 10 mg ezetimibe
- For LDL-C lowering in FH patients
Key takeaways
- US 11,744,816 is a method-of-use patent anchored on FH patient selection and exact dosing (180 mg 8-OH TDEA + 10 mg ezetimibe) for LDL-C lowering.
- Dependent claims add enforceable layers for fixed-dose combination and tablet formulation, plus hsCRP, VLDL, cardiovascular risk reduction, and once-daily dosing.
- Design-around leverage is mainly in deviating from one or more claim anchors: patient population (non-FH), dosing (not 180/10), dosing frequency (not once daily), not using a fixed-dose tablet (if only dependent claims are asserted), and differing biomarker/risk evidence for hsCRP/VLDL/cardiovascular risk dependent claims.
- Exclusivity timelines, Orange Book status, and litigation posture cannot be determined from the claim text alone.
FAQs
- Can a regimen that lowers LDL-C in high-risk patients without diagnosed familial hypercholesterolemia infringe Claim 1 of US 11,744,816?
- If a competitor administers 8-OH TDEA at a dose other than 180 mg with ezetimibe 10 mg, does that avoid literal infringement of Claim 1?
- Does administering the drugs as separate tablets instead of a fixed-dose tablet avoid Claim 2 and Claim 7, and does it still risk Claim 1?
- How would clinicians or litigators establish hsCRP reduction for Claim 3 as an infringement element?
- What development strategy best reduces risk of being accused under method-of-use patents covering FH-specific combination dosing?
References (APA)
- U.S. Patent 11,744,816.
More… ↓
⤷ Start Trial
|
